BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35243412)

  • 1. Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes.
    Plymate SR; Sprenger C; Haffner MC
    Cell Rep Med; 2022 Feb; 3(2):100493. PubMed ID: 35243412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
    Rice MA; Kumar V; Tailor D; Garcia-Marques FJ; Hsu EC; Liu S; Bermudez A; Kanchustambham V; Shankar V; Inde Z; Alabi BR; Muruganantham A; Shen M; Pandrala M; Nolley R; Aslan M; Ghoochani A; Agarwal A; Buckup M; Kumar M; Going CC; Peehl DM; Dixon SJ; Zare RN; Brooks JD; Pitteri SJ; Malhotra SV; Stoyanova T
    Cell Rep Med; 2022 Feb; 3(2):100502. PubMed ID: 35243415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the role of heat shock protein 90 in prostate cancer.
    Fu Z; Jia B
    Andrologia; 2022 May; 54(4):e14376. PubMed ID: 35075667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90: still a viable target in prostate cancer.
    Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
    Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.
    Albany C; Hahn NM
    Asian J Androl; 2014; 16(3):359-63. PubMed ID: 24713836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
    Moses MA; Henry EC; Ricke WA; Gasiewicz TA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.
    Hoang AT; Huang J; Rudra-Ganguly N; Zheng J; Powell WC; Rabindran SK; Wu C; Roy-Burman P
    Am J Pathol; 2000 Mar; 156(3):857-64. PubMed ID: 10702402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
    Ischia J; Saad F; Gleave M
    Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
    Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
    Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
    Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
    Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
    BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
    Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.
    Ding G; Feng C; Jiang H; Ding Q; Zhang L; Na R; Xu H; Liu J
    PLoS One; 2013; 8(10):e77400. PubMed ID: 24130883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
    Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
    Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor.
    Harashima K; Akimoto T; Nonaka T; Tsuzuki K; Mitsuhashi N; Nakano T
    Int J Radiat Biol; 2005 Jan; 81(1):63-76. PubMed ID: 15962764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
    Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
    Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.